Search results
Showing 511 to 525 of 667 results for diabetes
Find out more about NICE technology appraisals advisory committee D members
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.
This guideline covers recognising and managing antisocial behaviour and conduct disorders in children and young people aged under 19. It aims to improve care by identifying children and young people who are at risk and when interventions can prevent conduct disorders from developing. The guideline also makes recommendations on communication, to help professionals build relationships with children and young people and involve them in their own care.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
Liraglutide for the treatment of type 2 diabetes mellitus (TA203)
This guidance has been updated and replaced by NICE guideline NG28.
Diabetes: blood pressure (without moderate or severe frailty) (IND236)
This indicator has been updated and replaced by NICE indicator 249.
Guidance on the use of patient-education models for diabetes (TA60)
This guidance has been replaced by NICE guideline NG17.
In development Reference number: GID-TA11352 Expected publication date: TBC
This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.
View quality statements for QS9Show all sections
Sections for QS9
- Quality statements
- Quality statement 1: N-terminal pro-B-type natriuretic peptide measurement
- Quality statement 2: Specialist assessment
- Quality statement 3: Medication for newly diagnosed and pre-existing chronic heart failure with reduced ejection fraction
- Quality statement 4: Review after changes in medication
- Quality statement 5: Review of people with chronic heart failure
- Quality statement 6: Cardiac rehabilitation
- Update information
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (IPG518)
We have moved interventional procedures guidance 518 to become HealthTech guidance 371. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.